Back to available technologies

Methodology for treating HER2+ breast cancer with acquired lapatinib resistance

Methods of treating subjects with cancer and screening for MDM2 inhibitors that may be effective cancer therapeutics are provided herein. The cancers that may be treated using MDM2 inhibitors using the methods described herein include those that are or may become resistant to treatment with tyrosine kinase inhibitors. Methods of treating subjects with cancers that have, or develop in response to treatment with tyrosine kinase inhibitors, elevated levels of MDM2, Mcl-1 or PP5 or decreased levels of Huwel or CAS using MDM2 inhibitors are provided herein. The MDM2 inhibitors may be effective at treating these cancers alone or in combination with a tyrosine kinase inhibitor regardless of p53 status (mutant or wild-type) of the cancer.

Duke File (IDF) Number

T-003726

Inventor(s)

  • Kornbluth, Sally
  • Dewhirst, Mark
  • Kurokawa, Manabu
  • Spector, Neil

For more information please contact

College

School of Medicine (SOM)

Interested in this Technology?

Submit your interest below.